Login to Your Account



Biogen Idec Turns in Strong Year-End Results

By Catherine Shaffer


Wednesday, February 2, 2011
Biogen Idec's revenues for 2010 exceeded the prior year by 8 percent, coming in at $4.7 billion. Tysabri drove much of the growth, with $900 million in revenues, and solid returns for Avonex and Rituxan. Throughout 2010, the company has pursued a strategy of whittling down nonperforming programs, in-licensing products in its areas of strength and expanding labeling and indications for its approved products, and shows every indication of continuing strong in 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription